Prostate Cancer Trial, Recruiting NCT07672119 Sponsor: Bayer Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT07672119
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are male and have been diagnosed with prostate cancer
  • People who have had at least 2 prescription records for either enzalutamide or darolutamide during a specific time period identified by the trial
  • People who had a diagnosis of either hormone-sensitive prostate cancer that has spread (mHSPC) or non-metastatic castration-resistant prostate cancer (nmCRPC) on or before the start date set by the trial (confirm with trial site)
  • People who were aged 55 or older at the time of that start date

Who may not be able to join:

  • People who have prior use of certain prostate cancer medicines (abiraterone, apalutamide, enzalutamide, or darolutamide) before the trial start date, or who show evidence of castration-resistant prostate cancer before the trial start date — this applies specifically to those with hormone-sensitive prostate cancer that has spread (confirm with trial site)
  • People with non-metastatic castration-resistant prostate cancer who show evidence that the cancer had already spread to other parts of the body within the first 30 days after the trial start date

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 18888422937

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
4 June 2026
Est. completion
29 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence proportion and incidence rate (per 100 person-years) of 3-point major cardiovascular event (MACE); Estimation of the association of risk factors with 3-point MACE

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov